Foxp3 protein governs regulatory T cell genome structure
Foxp3 alters chromatin architecture of regulatory T cells, meaning Foxp3 could become a target for therapies that modulate immunosuppression.
List view / Grid view
Foxp3 alters chromatin architecture of regulatory T cells, meaning Foxp3 could become a target for therapies that modulate immunosuppression.
Researchers have developed a new bioreactor that can manufacture T cells faster than other technologies, which may advance immunotherapy.
Researchers have found that reducing glycosylation on the T cell surface may offer new approaches to cancer immunotherapy.
4 October 2023 | By Halo Labs
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
A collaborative team has uncovered a method to extend the functionality of CAR-T cells.
New research shows T cells use the nuclear receptor RARα not just for gene regulation, but also to trigger cell surface events that activate them against pathogens and cancer.
BlueSphere Bio's TCXpress platform revolutionises the isolation and functional characterisation of T-cell receptors (TCRs) with unparalleled speed and efficiency, enabling rapid identification of unique TCRs from thousands of individual T cells within days.
Researchers from the University of Freiburg and the University of Cambridge have observed live cell formation of membraneless molecular aggregates, uncovering the interplay between biological mechanisms and physical force.
A new discovery presents a bioinformatic approach for improving vaccine effectiveness against infectious agents such as COVID-19.
This episode defines allogeneic cell therapy as the administration of cells to a patient for therapeutic use, that were not initially taken from that patient.
Australian researchers analyse the way specialised white blood cells produce an immune response, which could lead to the development of preventative treatments for cancer and infectious diseases.
14 July 2023 | By BPS Bioscience
Watch this webinar to get an overview of the CAR-T workflow and learn about the latest CAR-T research enabling tools that can accelerate your discovery.
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
In this article, Drug Target Review's Izzy Wood uncovers the cutting-edge breakthroughs in T cell research that are revolutionising our understanding of the immune system and paving the way for new therapies and treatments.